Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Reumabase.it

Search results for "Psoriatic arthritis"

A prospective cohort study found that Tumour Necrosis Factor alpha ( TNF-alpha ) blocking agents, trigger skin conditions in 25% of patients with rheumatoid arthtitis. TNF-alpha blocking agents has ...


FDA ( Food and Drug Administration ) has approved Remicade ( Infliximab ) to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis. Psoriatic arthritis affects ap ...


FDA ( U.S. Food and Drug Administration ) approved Humira ( Adalimumab ) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis, a chronic disease that combines the ...


Any form of arthritis that affects one or more vertebral joints, spondylarthritis ( SpA ) represents a group of closely related disorders, including ankylosing spondylitis ( AS ), psoriatic arthriti ...


Patients with active psoriatic arthritis receiving monthly subcutaneous injections of Golimumab ( Simponi ) experienced significant and sustained improvements in the joint and skin manifestations ...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in systemic or biologic DMARD-naïve psoriatic arthritis patients.PAL ...


Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody Ustekin ...


Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional tr ...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of adult patients with active psoriatic arth ...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast a ...


Patients with rheumatoid arthritis and carotid artery plaques have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol ( LDL-c ) goal  less than or eq ...


Most incident cases of psoriatic arthritis ( PsA ) present among patients with pre-existing psoriasis, and because of the high absolute prevalence of psoriatic arthritis among psoriasis patients this ...


Since the publication of the European League Against Rheumatism ( EULAR ) recommendations for the pharmacological treatment of psoriatic arthritis ( PsA ) in 2012, new evidence and new therapeutic age ...


Interleukin-17A ( IL-17A ) is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, Secukinumab ( Cosentyx ), a fully human anti-IL-17A monoclonal antibody ...


A study has described the long-term adherence, efficacy, and safety in patients with psoriatic arthritis ( PsA ) treated with Etanercept ( Enbrel ) in a daily clinical setting in Belgium. The PROVE ...